Tianfeng Xu

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Xin Han, Chao Wang, Chong Qin et al. · Journal of Medicinal Chemistry · 2019 · 371 citations · Full text

Androgen Receptor, Urology, Drug Targeting +11

Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands

Xin Han, Lijie Zhao, Weiguo Xiang et al. · Journal of Medicinal Chemistry · 2019 · 208 citations · Full text

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Jing Gao, Bo Hou, Qiwen Zhu et al. · Nature Communications · 2022 · 184 citations · Full text

Copper-Catalyzed Tandem Reactions of 1-(2-Iodoary)-2-yn-1-ones with Isocyanides for the Synthesis of 4-Oxo-indeno[1,2-<i>b</i>]pyrroles

Qian Cai, Fengtao Zhou, Tianfeng Xu et al. · Organic Letters · 2010 · 94 citations

Chemical Engineering, Copper-catalyzed Tandem Reactions, Engineering +8

Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine⁷⁹⁰ → Methionine⁷⁹⁰ Mutant

Shaohua Chang, Lianwen Zhang, Shilin Xu et al. · Journal of Medicinal Chemistry · 2012 · 83 citations · Full text

Drug Target, Engineering, Molecular Biology +20